budoprutug
AssetAlso TNT119, VB-119
Anti-CD19 monoclonal antibody that depletes B cells to reduce pathogenic autoantibody production.
- Stage
- Phase 2
- Modality
- Antibody
- Target
- CD19
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Primary membranous nephropathy
Phase 2, Recruiting, NCT07096843, clinicaltrials.gov, 11 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors7
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.